OptiBiotix Health's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 78.79.
OptiBiotix Health's Days Inventory for the
six
months ended in Dec. 2025 was 216.05.
OptiBiotix Health's Days Payable for the
six
months ended in Dec. 2025 was 197.26.
Therefore, OptiBiotix Health's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 97.58.
OptiBiotix Health (STU:OB3) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
OptiBiotix Health Cash Conversion Cycle Related Terms
OptiBiotix Health Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for OptiBiotix Health's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OB3 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, OptiBiotix Health's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptiBiotix Health Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OptiBiotix Health's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where OptiBiotix Health's Cash Conversion Cycle falls into.
OptiBiotix Health Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
OptiBiotix Health's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptiBiotix Health (STU:OB3) has a Cash Conversion Cycle of 97.58 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on OptiBiotix Health and its competitors.
Is OptiBiotix Health's Cash Conversion Cycle too high?
OptiBiotix Health's current Cash Conversion Cycle is 97.58. The Biotechnology industry median Cash Conversion Cycle is 104.03. OptiBiotix Health's value of 97.58 is 6.2% below this industry median.
How does OptiBiotix Health's Cash Conversion Cycle compare to VRTX and REGN?
OptiBiotix Health's Cash Conversion Cycle of 97.58 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.03. OptiBiotix Health's value of 97.58 is 6.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.03, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OptiBiotix Health's current Cash Conversion Cycle of 97.58 is 6.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on OptiBiotix Health and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OptiBiotix Health's current Cash Conversion Cycle is 97.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
OptiBiotix Health (STU:OB3) has a current Cash Conversion Cycle of 97.58. The stock's GF Value™ is €0.34, compared to a current price of €0.07 — trading 78.5% below its estimated fair value. The current Cash Conversion Cycle is 97.58 and 6.2% below the Biotechnology industry median of 104.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For OptiBiotix Health (STU:OB3), the current Cash Conversion Cycle is 97.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OB3 has been successfully added to your 